GonorrhoeaPhase 2NCT04722003
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
A Phase 2 study testing Meningococcal Group B Vaccine in people with Gonorrhoea, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.
Trial summary
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae, using a placebo vaccine (normal saline) as a comparator (group 2, 10 subjects). Read more about this study
- Who is it for?
- Ages 18 to 49 yearsHealthy volunteers can take part
- Conditions the study is for
- Gonorrhoea
- What is being tested?
- Meningococcal Group B Vaccine
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 52 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2021to 2 Oct 2023
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Must be aged 18-49 years old (inclusive) at the time of vaccination.
- Must be able to provide written informed consent.
- Must have a body mass index (BMI) >/= 18.5 and < 35.0 kg/m2
- Must be in good health based on physical examination, vital signs*, medical history, safety labs** (as applicable to the rectal biopsy and no biopsy cohorts) and the investigator's clinical judgment.
- Vital signs must be within the normal ranges. If a subject has elevated systolic or diastolic blood pressure, subject may rest for 10 minutes in a quiet room and the blood pressure may be retaken.
- Safety labs must be within the normal ranges and the normal ranges will be those used by the reference clinical lab.
Show all 12Show fewer
- For female subjects only: If a female participant is of childbearing potential*, she must use contraception** from 30 days before study product administration through the end of study participation.
- A woman is considered of childbearing potential unless post-menopausal (defined as history of >/= 1 year of spontaneous amenorrhea), or permanently surgically sterilized (bilateral oophorectomy, salpingectomy, hysterectomy).
- Acceptable methods of contraception include: abstinence or no sex with a male, monogamous relationship with a man who had a vasectomy at least 6 months before the 1st study vaccine, prescription oral contraceptives, intrauterine device (IUD), birth control implants or injections, contraceptive patch, vaginal ring, condoms and diaphragms/cervical cap with spermicide ("double barrier" method).
- Must be available and willing to participate for the duration of this trial.
- Willing to provide mucosal samples: vaginal secretions for women and oropharyngeal and rectal secretions for men and women.
- For the rectal biopsy cohort only, willing to provide rectal biopsies.
Who cannot join
- Has ever been diagnosed with meningococcal infection or gonococcal infection at any anatomic site.
- Has ever received any serogroup B meningococcal vaccine.
- Any positive test result for STI (including Neisseria gonorrhoeae (GC) Chlamydia trachomatis (CT), Rapid Plasma Reagin (RPR) and Human Immunodeficiency Virus (HIV)) at screening*.
- Female subjects will also be tested for Trichomonas at screening.
- Any history of Chlamydia trachomatis or syphilis infection at any body site in the preceding 12 months
- Has known allergy or history of anaphylaxis or other serious adverse reaction to a vaccine or vaccine products.
Show all 33Show fewer
- Has severe allergy or anaphylaxis to latex.
- Has an acute illness or temperature >/= 38.0 degrees Celsius on Day 1*.
- Subjects with fever or acute illness on the day of vaccination may be re-assessed and enrolled if healthy or only minor residual symptoms remain within 3 days.
- Has a history of a bleeding disorder, or is taking chronic anti-coagulant (e.g. warfarin, direct thrombin inhibitors, heparin products, etc.), anti-platelet, or non-steroidal anti-inflammatory drugs (NSAID) therapy.
- Has history of autoimmune disease, or clinically significant cardiac, pulmonary, gastrointestinal, hepatic, rheumatologic, or renal disease by history or physical examination.
- Has history of active malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure*.
- Subjects with a history of skin cancer must not be vaccinated at the previous tumor site.
- Has known or suspected congenital or acquired immunodeficiency, or recent history or current use of immunosuppressive therapy*.
- Anti-cancer chemotherapy or radiation therapy within the preceding 3 years, or long-term (>/= 2 weeks within the previous 3 months) systemic corticosteroid therapy (at a dosage of >/= 0.5 mg/kg/day). Intranasal or topical prednisone (or equivalent) are allowed.
- Is post-organ and/or stem cell transplant, whether or not on chronic immunosuppressive therapy.
- Had major surgery (per the investigator's judgment) within 4 weeks before study entry or planned major surgery during this trial.
- Has history of diabetes* mellitus type 1 or type 2, including cases controlled with diet alone*.
- History of isolated gestational diabetes is not an exclusion criterion.
- Received live attenuated vaccines from 30 days before first vaccination until 30 days after second vaccination.
- Received killed or inactivated vaccines* from 14 days before first vaccination until 14 days after second vaccination.
- For inactivated influenza vaccine, from 7 days before either vaccination until 7 days after either vaccination.
- Received mRNA, viral vector, or any other technology platform Corona Virus Disease-19 (COVID-19) vaccine within 14 days prior to first dose of the study product.*
- COVID-19 vaccination should take priority over administration of the study product.
- Received experimental therapeutic agents within 12 months before first vaccination or plans to receive any experimental therapeutic agents during this trial except for Emergency Use Authorization (EUA) COVID-19 therapy.*
- Only exclusionary if, in the opinion of the investigator, they would interfere with safety or endpoint assessment.
- Is currently participating or plans to participate in another clinical study which would involve receipt of an investigational product or undergoing a procedure*.
- Only exclusionary if, in the opinion of the investigator, they would interfere with safety or endpoint assessment.
- Received blood products or immunoglobulin in the 3 months before study entry or planned use during this trial.
- Has major psychiatric illness in the past 12 months that in the opinion of the investigator would preclude participation.
- Has current alcohol use or current or past abuse of recreational or narcotic drugs by history as judged by the investigator to potentially interfere with study adherence.
- In the opinion of the investigator cannot communicate reliably, is unlikely to adhere to the requirements of this trial, or has any condition which would limit the ability to complete this trial.
- Is pregnant or breast feeding.
Trial locations and contacts
1 site in 1 country.
United States1 site
The Hope Clinic of Emory University
Decatur, Georgia, 30030-1705
About this study
Official title: Mucosal Immune Responses Against Neisseria Gonorrhoeae Following Meningococcal Immunization in Healthy Young Adults
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae, using a placebo vaccine (normal saline) as a comparator (group 2, 10 subjects). There will be approximately 50 participants, ages 18-49, both male and non-pregnant female subjects, enrolled at 1 site in the US. The goal will be to ensure adequate representation of subjects by sex in both treatment groups. The enrollment will be stratified by both sex and treatment arm. During enrollment of the "biopsy cohort" male and non-pregnant female subjects will be randomized 4:1 to either 4CMenB or placebo, up to a maximum of 10 male and 10 non-pregnant female subjects. Group 1 (approximate N=40) will receive two doses of 4CMenB on Day 1 and Day 29. Group 2 (approximate N=10) will receive two placebo injections on Day 1 and Day 29. Both groups will receive a single-dose prefilled syringe that is administered intramuscularly (0.5-mililiter each). The duration of each subject's participation is approximately 8 months, from recruitment through the last study visit, and the length of the study is estimated for 14 months. The primary objective is to characterize the rectal mucosal Immunoglobulin G IgG antibody response to Neisseria gonorrhoeae (GC) elicited by the 4CMenB vaccine as compared with the placebo vaccine (normal saline) in healthy adult subjects.
Read the detailed description
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae, using a placebo vaccine (normal saline) as a comparator (group 2, 10 subjects). There will be approximately 50 participants, ages 18-49, both male and non-pregnant female subjects, enrolled at 1 site in the US. The goal will be to ensure adequate representation of subjects by sex in both treatment groups. The enrollment will be stratified by both sex and treatment arm. A subset of subjects in each treatment group (N=16 in Group 1, N=4 in Group 2) will undergo rectal mucosal biopsy at two time points (baseline and following the second vaccination) for assessment of tissue Neisseria gonorrhoeae (GC) specific cellular responses. During enrollment of the "biopsy cohort" male and non-pregnant female subjects will be randomized 4:1 to either 4CMenB or placebo, up to a maximum of 10 male and 10 non-pregnant female subjects. All subjects will undergo sampling of mucosal secretions for testing for antibodies against Neisseria gonorrhoeae (GC). Male subjects will undergo oropharyngeal and rectal mucosal sampling, and female subjects will undergo oropharyngeal, vaginal and rectal mucosal sampling. Group 1 (approximate N=40) will receive two doses of 4CMenB on Day 1 and Day 29. Group 2 (approximate N=10) will receive two placebo injections on Day 1 and Day 29. Both groups will receive a single-dose prefilled syringe that is administered intramuscularly (0.5-mililter each). The duration of each subject's participation is approximately 8 months, from recruitment through the last study visit, and the length of the study is estimated for 14 months. The primary objective is to characterize the rectal mucosal Immunoglobulin G (IgG) antibody response to Neisseria gonorrhoeae (GC) elicited by the 4CMenB vaccine as compared with the placebo vaccine (normal saline) in healthy adult subjects. The secondary objectives are: 1) To characterize the serum IgG antibody response to Neisseria gonorrhoeae (GC) elicited by the 4CMenB vaccine as compared with the placebo vaccine in healthy adult subjects, 2) To assess the safety and reactogenicity of 4CMenB in healthy adult subjects.
- Conditions
- Gonorrhoea
- Being tested
- Meningococcal Group B Vaccine, Placebo
- Keywords
- 4CMenB, Gonorrhea, Meningococcal Group B Vaccine, Meningococcal Immunization, Mucosal Immune Response, Neisseria gonorrhoeae
- Medical subject headings
- Gonorrhea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Meningococcal Group B VaccineBiological
A combination vaccine consisting of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), Outer Membrane Vesicles (OMV), aluminum hydroxide, sodium chloride, histidine, and sucrose.
PlaceboOther
0.9% Sodium Chloride, USP injection.
| Study group | Role | What they receive |
|---|---|---|
| 4CMenB | Experimental | Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40 Receives: Biological: Meningococcal Group B Vaccine |
| Placebo | Placebo comparator | Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10 Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Geometric Mean of Percentage of Total IgG in Rectal Mucosal Specimens Against OMV Ng 1291 Antigens
The geometric mean of the percentage of total IgG in rectal mucosal specimens against OMV Ng 1291 antigens by ELISA taken across participants in each treatment group at Day 1, 29, 43, 57, and 181.
Measured: Day 1, 29, 43, 57, and 181.
Geometric Mean of Percentage of Total IgG in Rectal Mucosal Specimens Against OMV CNG20 Antigens
The geometric mean of the percentage of total IgG in rectal mucosal specimens against OMV CNG20 antigens by ELISA taken across participants in each treatment group at Day 1, 29, 43, 57, and 181.
Measured: Day 1, 29, 43, 57, and 181.
Secondary outcomes (4)
Geometric Mean of Serum IgG Antibody Response to OMV Ng1291 Antigens
This outcome measure presents the geometric mean serum IgG antibody response to OMV Ng1291 antigens in each treatment group at Days 1, 29, 43, 57, and 181. Serum IgG antibody response to OMV Ng1291 antigens was measured via enzyme-linked immunosorbent assay (ELISA) and presented as the area under the absorption vs concentration curve, where absorption is the optical density measured at 450 nanometers (OD450) and concentration is the reciprocal dilution factor.
Measured: Day 1, 29, 43, 57, and 181
Geometric Mean of Serum IgG Antibody Response to OMV CNG20 Antigens
This outcome measure presents the geometric mean serum IgG antibody response to OMV CNG20 antigens in each treatment group at Days 1, 29, 43, 57, and 181. Serum IgG antibody response to OMV CNG20 antigens was measured via enzyme-linked immunosorbent assay (ELISA) and presented as the area under the absorption vs concentration curve, where absorption is the optical density measured at 450 nanometers (OD450) and concentration is the reciprocal dilution factor.
Measured: Day 1, 29, 43, 57, and 181
The Reactogenicity of 4CMenB in Healthy Adult Participants
Frequency and severity of any adverse events (AE) related to 4CMenB immunization
Measured: Day 1 through Day 181
Frequency of Serious Adverse Events (SAE)
Frequency of SAEs through the end of the study.
Measured: Day 1 through Day 181
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2021
- Study start1 Nov 2021
- Primary completion2 Oct 2023
- Study completion2 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for GonorrhoeaStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 52 participants (actual)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04722003
- Sponsor's protocol ID
- 19-0015
- Other IDs
- 5UM1AI148576-05
- Status last verified
- 22 Jun 2026
- First submitted
- 21 Jan 2021
- Last updated
- 21 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No